Loading…
Legend Biotech Corporation is projected to rise to $34.90 by 2027, a +22% move from its current price of $28.50. LEGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $27.53 | $28.53 | $29.56 | +0.09% |
| May 30 | $27.15 | $28.55 | $30.02 | +0.18% |
| May 31 | $26.87 | $28.58 | $30.39 | +0.26% |
| Jun 1 | $26.63 | $28.60 | $30.71 | +0.35% |
| Jun 2 | $26.43 | $28.63 | $31.00 | +0.44% |
| Jun 3 | $26.26 | $28.65 | $31.26 | +0.53% |
| Jun 4 | $26.10 | $28.68 | $31.51 | +0.62% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.10 | $28.68 | $31.51 | +0.62% |
| Week 2 | $25.25 | $28.85 | $32.96 | +1.24% |
| Week 3 | $24.66 | $29.03 | $34.18 | +1.86% |
| Week 4 | $24.19 | $29.21 | $35.27 | +2.49% |
| Week 5 | $23.81 | $29.39 | $36.28 | +3.12% |
| Week 6 | $23.48 | $29.57 | $37.25 | +3.76% |
| Week 7 | $23.19 | $29.75 | $38.18 | +4.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Legend Biotech also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting BCMA for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc.
for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein.
Legend Biotech Corporation (LEGN) is in the healthcare sector with a current price of $29.37 and a market capitalization of $5.46B. It is ranked 1283.
The stock’s near-term outlook reflects a 2026 average price of $29.37 with a range of $16.65 to $41.60 and a Neutral sentiment. This year marks a baseline from which longer-term upside is projected.
From 2027 onward, the forecast shows bullish momentum, with 2027 average $36.23 and 2030 average $44.49, supported by rising risk-adjusted expectations. The sequence includes 2040 average $121.86 and 2050 average $225.77, with corresponding max prices and strong ROI figures. The 30-day range is $22.99 to $37.51, and annualized volatility is 70%.
A major floor 41.6% below — a decisive break under it would weaken the trend.
The nearest floor, 28.0% below — buyers have tended to step in here.
The nearest ceiling, 3.6% above — a clean break opens room to run.
A major ceiling 23.5% above — clearing it would confirm fresh momentum.
Key LEGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LEGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $28.70 | Sell | $28.63 | Sell |
| MA 10 | $28.23 | Buy | $28.20 | Buy |
| MA 20 | $27.33 | Buy | $27.08 | Buy |
| MA 50 | $22.81 | Buy | $24.38 | Buy |
| MA 100 | $21.10 | Buy | $23.61 | Buy |
| MA 200 | $25.98 | Buy | $25.87 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.32 | Neutral |
| Stoch RSI (14) | 15.11 | Buy |
| CCI (20) | 50.45 | Neutral |
| Williams %R (14) | -26.08 | Info |
| MACD (12,26,9) | -0.12 | Sell |
| ROC (12) | 1.35 | Buy |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 73.92 | Neutral |
| TRIX (15) | 1.10 | Buy |
| Awesome (5,34) | 3.60 | Buy |
| Ultimate (7,14,28) | 57.52 | Neutral |
| Momentum (10) | 0.24 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 29.43 | Sell |
| ADX (14) | 27.94 | Buy |
| ATR (14) | 0.83 | Info |
The near-term technical picture remains bullish overall, with RSI14 at 70 and the price trading above the SMA50 of $22.40 and the SMA200 of $26.06. A key near-term resistance sits at $29.37, while support is indicated at $17.69. The 30-day range spans from $22.99 to $37.51, signaling room to move within a broad trading band before a defined breakout.
These dynamics suggest upside potential but also the risk of pullbacks given the current overbought-like RSI level and the high volatility environment, as reflected by the 70% annualized volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.65 | $28.50 | $40.16 | 0% | Neutral | |
| $26.86 | $34.90 | $48.49 | +22% | Bullish | |
| $29.46 | $39.70 | $57.66 | +39% | Bullish | |
| $27.15 | $37.74 | $56.76 | +32% | Bullish | |
| $30.21 | $43.16 | $66.86 | +51% | Bullish | |
| $36.58 | $53.62 | $85.21 | +88% | Bullish | |
| $41.68 | $62.57 | $101.74 | +120% | Bullish | |
| $46.89 | $72.01 | $119.55 | +153% | Bullish | |
| $44.52 | $69.86 | $118.21 | +145% | Bullish | |
| $43.30 | $69.38 | $119.47 | +143% | Bullish | |
| $67.39 | $118.91 | $220.38 | +317% | Bullish | |
| $104.38 | $219.16 | $451.43 | +669% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $16.65 | $28.50 | $33.60 | +0.00% |
| June 2026 | $25.06 | $29.62 | $35.99 | +3.93% |
| July 2026 | $25.83 | $30.88 | $38.18 | +4.25% |
| August 2026 | $25.32 | $30.53 | $38.25 | -1.13% |
| September 2026 | $25.09 | $30.47 | $38.58 | -0.21% |
| October 2026 | $25.84 | $31.59 | $40.40 | +3.70% |
| November 2026 | $25.78 | $31.70 | $40.89 | +0.35% |
| December 2026 | $24.98 | $30.89 | $40.16 | -2.57% |
Click any year to see its month-by-month LEGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, LEGN could reach as high as $40.16, with a base case around $28.50 and support toward $16.65 — roughly 0% from $28.50. A consolidation phase looks the most probable path here.
Expect LEGN to range from $26.86 to $48.49 through 2027. The $34.90 average target implies a +22% move from current prices. That is up +22% on the projected 2026 average. Momentum favours further upside here.
The LEGN price prediction for 2028 points to an average of $39.70 (low $29.46, high $57.66) — a potential gain of +39% on today's $28.50. Buyers look set to stay in control over this stretch.
In 2029, LEGN is projected to trade between $27.15 and $56.76, averaging $37.74 — a potential gain of +32% from today's $28.50. That is -5% versus the projected 2028 average. Momentum favours further upside here.
Legend Biotech Corporation's 2030 outlook centres on $43.16, within a $30.21 to $66.86 range. That is up +14% on the projected 2029 average. That marks a +51% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, LEGN could reach as high as $85.21, with a base case around $53.62 and support toward $36.58 — roughly +88% from $28.50. Momentum favours further upside here.
Expect LEGN to range from $41.68 to $101.74 through 2032. The $62.57 average target implies a +120% move from current prices. That is up +17% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The LEGN price prediction for 2033 points to an average of $72.01 (low $46.89, high $119.55) — a potential gain of +153% on today's $28.50. Momentum favours further upside here.
In 2034, LEGN is projected to trade between $44.52 and $118.21, averaging $69.86 — a potential gain of +145% from today's $28.50. That is -3% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
Legend Biotech Corporation's 2035 outlook centres on $69.38, within a $43.30 to $119.47 range. That is -1% versus the projected 2034 average. That marks a +143% change versus current levels. Momentum favours further upside here.
By 2040, LEGN could reach as high as $220.38, with a base case around $118.91 and support toward $67.39 — roughly +317% from $28.50. Buyers look set to stay in control over this stretch.
Expect LEGN to range from $104.38 to $451.43 through 2050. The $219.16 average target implies a +669% move from current prices. That is up +84% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in LEGN today (≈ 35.087719 LEGN) could be worth
$7,689.67
+$6,689.67 (+669%) by 2050 · US Dollar
Based on the average projected LEGN price of $219.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LEGNwould be worth at today's price.
$1,000 invested in LEGN on May 27, 2025 (≈ 34.770514 LEGN) would be worth
$990.96
-$9.04 (-0.9%) today · 0.99× · US Dollar
Based on a LEGN entry price of $28.76 vs. today's $28.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $28.12 | $1,013.51 | +1.4% |
| 1 month ago | $23.65 | $1,205.07 | +20.5% |
| 3 months ago | $19.28 | $1,478.22 | +47.8% |
| 6 months ago | $27.71 | $1,028.51 | +2.9% |
| 1 year ago | $28.76 | $990.96 | -0.9% |
| All time (5.0y) ago | $38.76 | $735.29 | -26.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LEGN forecast.
Our base-case forecast reaches $57.00 around 2032.
Implied market cap at $57.00: $10.59B
The multi-year forecast paints a steadily higher path for Legend Biotech. The 2026 average price is $29.37 with a neutral sentiment, followed by a bullish trajectory in subsequent years. The 2027 average is $36.23, the 2028 average is $40.85, and the 2029 average is $38.46, with 2030 averaging $44.49 and a 51.5% ROI.
Beyond 2030, the forecast extends into 2040 with an average of $121.86 and a 314.9% ROI, and into 2050 with an average of $225.77 and a 668.7% ROI. The bullish sentiment persists across 2031–2050. However, the high volatility noted (70%) implies substantial price swings and uncertainty around these estimates.
In sum, the long-term view envisions meaningful upside, anchored by higher projected averages and substantial ROI potential, but with notable risk.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $44.49 with a max of $69.68 and a min of $30.79, and a ROI of 51.5% with bullish sentiment.
Forecasts indicate a bullish sentiment in 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2040, and 2050, with rising average prices and ROI: 2027 avg $36.23 (23.4% ROI), 2030 avg $44.49 (51.5%), 2040 avg $121.86 (314.9%), 2050 avg $225.77 (668.7%). 2026 is neutral with avg $29.37 and ROI 0.
Yes. The forecast shows 2032 has a max of $106.30, with 2032 avg $64.56 and min $42.42, indicating it can exceed $100 according to the model’s projections.
The 30-day range is $22.99 to $37.51, and annualized volatility is 70%.
Legend Biotech Corporation Community Discussion
0Share your Legend Biotech Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.